RA
SPRO icon

Royce & Associates’s Spero Therapeutics SPRO Stock Holding History

Royce & Associates’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-22,851
Closed -$33.1K – 945
2023
Q2 		$33.1K Buy
+22,851
New +$39.1K ﹤0.01% 910

Other funds holding SPRO

AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Royce & Associates's SPRO Position: Q3 2023 in Review

Royce & Associates sold out of Spero Therapeutics (SPRO) in Q3 2023, closing a stake of 22,851 shares — an estimated $33.1K sold.

Royce & Associates first reported a position in SPRO in Q2 2023 and held it in 1 quarter. The position peaked at $33.1K in Q2 2023. 54 funds tracked by Wall St. Rank hold SPRO as of Q3 2023.

  • Royce & Associates reported no remaining Spero Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Royce & Associates sold 22,851 Spero Therapeutics shares in Q3 2023, an estimated $33.1K.
  • Royce & Associates first reported a position in Spero Therapeutics in Q2 2023 and held it in 1 quarter.
  • Royce & Associates's Spero Therapeutics position peaked at $33.1K in Q2 2023.
  • 54 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2023.

Based on Royce & Associates's 13F filing for Q3 2023, filed 9 Nov 2023.